Hepatitis B Virus News and Research

RSS

Researchers seek virus genes that allow animal hepatitis E strains infect humans

X.J. Meng, a University Distinguished Professor at Virginia Tech and a virologist at the Virginia-Maryland Regional College of Veterinary Medicine, has received a four-year, nearly $1.6 million grant from the National Institutes of Health to better understand the genetic elements that allow hepatitis E virus to transfer from animals to people.

17 Jul 2013

Researchers identify genes that allow animal hepatitis E virus strains to infect humans

16 Jul 2013

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

Sorrento Therapeutics, Inc. and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev, have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus.

10 Jul 2013

FDA to restrain shipments of pomegranate seeds from Turkey after hepatitis A outbreak

The U.S. Food and Drug Administration will detain shipments of pomegranate seeds from Goknur Gida Maddeleri Ithalat Ihracat Tic [Goknur Foodstuffs Import Export Trading] of Turkey when they are offered for import into the United States.

1 Jul 2013

Abbott RealTime HCV Genotype II assay receives FDA approval

The U.S. Food and Drug Administration today approved a test that identifies the genotype of hepatitis C virus that a patient is carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an infected patient's blood plasma or serum, will aid health care professionals in determining the appropriate approach to treatment.

21 Jun 2013

Accenture: Boom ahead for retail health clinics

According to the consulting firm Accenture, the number of retail clinics will likely double by the end of 2015 -- a trend fueled by the demand for care by consumers who will become insured under the health law. Meanwhile, the Fiscal Times examines why some physicians are choosing not to accept any health insurance.

14 Jun 2013

First Edition: June 13, 2013

Today's headlines include reports about how employers are preparing for some parts of the health law to kick in.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Study shows iron-uptake receptor plays a role in HCV infection

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Liver regeneration using cell therapy may be possible, study suggests

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the online journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.

10 Jun 2013

Low levels of vitamin D associated with high levels of hepatitis B virus replication

Researchers from Germany have found that low levels of vitamin D are associated with high levels of hepatitis B virus replication. Findings published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggest seasonal fluctuations in vitamin D and HBV levels point to a link in these variables among patients with chronic HBV.

6 Jun 2013

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen.

3 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

JPIDS releases consensus statement of Sentinel Project on Pediatric Drug-Resistant Tuberculosis

The Journal of the Pediatric Infectious Diseases Society today released its June issue, which includes a consensus statement of the global Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

22 May 2013

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.

22 May 2013

Gilead Sciences' sofosbuvir MAA gets EMA validation

Gilead Sciences, Inc. today announced that the company's Marketing Authorisation Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection, which was submitted to the European Medicines Agency on April 17, 2013, has been fully validated and is now under assessment.

22 May 2013

Understanding different forms of hepatitis

It's Hepatitis Awareness Month. Understanding the different forms of hepatitis, who is at risk and how it can be prevented and treated can be confusing.

14 May 2013

Scientists identify new way to boost gene-silencing mechanism

A team led by scientists at The Scripps Research Institute (TSRI) has found how to boost or inhibit a gene-silencing mechanism that normally serves as a major controller of cells' activities. The discovery could lead to a powerful new class of drugs against viral infections, cancers and other diseases.

10 May 2013

Hepatitis B Virus News and Research

Researchers seek virus genes that allow animal hepatitis E strains infect humans

Researchers identify genes that allow animal hepatitis E virus strains to infect humans

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

FDA to restrain shipments of pomegranate seeds from Turkey after hepatitis A outbreak

Abbott RealTime HCV Genotype II assay receives FDA approval

Accenture: Boom ahead for retail health clinics

First Edition: June 13, 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Study shows iron-uptake receptor plays a role in HCV infection

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Liver regeneration using cell therapy may be possible, study suggests

Low levels of vitamin D associated with high levels of hepatitis B virus replication

Researchers develop RNA aptamers that inhibit HCV replication

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

JPIDS releases consensus statement of Sentinel Project on Pediatric Drug-Resistant Tuberculosis

Experts urge baby boomers to get screened for HCV

Gilead Sciences' sofosbuvir MAA gets EMA validation

Understanding different forms of hepatitis

Scientists identify new way to boost gene-silencing mechanism

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News